[{"id":"63b7f842-7dbd-4050-9b6c-f6c0d81db8df","acronym":"(MARGARET)","url":"https://clinicaltrials.gov/study/NCT04683250","created_at":"2021-01-19T20:47:05.192Z","updated_at":"2025-02-25T14:02:08.938Z","phase":"Phase 1/2","brief_title":"Study of RET Inhibitor TAS0953/HM06 in Patients with Advanced Solid Tumors with RET Gene Abnormalities","source_id_and_acronym":"NCT04683250 - (MARGARET)","lead_sponsor":"Taiho Pharmaceutical Co., Ltd.","biomarkers":" RET","pipe":" | ","alterations":" RET fusion","tags":["RET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RET fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e vepafestinib (TAS0953/HM06)"],"overall_status":"Recruiting","enrollment":" Enrollment 202","initiation":"Initiation: 12/16/2020","start_date":" 12/16/2020","primary_txt":" Primary completion: 03/01/2030","primary_completion_date":" 03/01/2030","study_txt":" Completion: 03/01/2031","study_completion_date":" 03/01/2031","last_update_posted":"2025-02-14"}]